Literature DB >> 3100459

Generation of activated killer cells in tumor-bearing hosts.

C C Ting, M E Hargrove, D Stephany.   

Abstract

Activated killer (AK) cells were generated in spleen-cell cultures derived from tumor-bearing hosts (TS) whereas, under the same conditions, cultured normal spleen cells (NS) gave little cytotoxicity. The AK effectors were primarily Thy1+, AGM1- and Lyt2- and thus were neither classic cytotoxic T lymphocytes (CTL) nor classic NK cells. These AK cells selectively killed tumor targets of different etiologic origins and did not kill concanavalin-A-induced lymphoblasts. The broad target-cell reactivity of these AK cells was also confirmed by cold target-inhibition experiments. Generation of AK cell correlated with interleukin-2 (IL-2) production, and the levels of AK cells generation paralleled those of IL-2 production. Furthermore, the generation of AK cells was blocked by the anti-IL-2 receptor monoclonal antibody (MAb) (alpha IL-2R), indicating that IL-2 was involved, and thus these AK cells were lymphokine-activated killer (LAK) cells. We previously showed that the expression of AGM1 on LAK precursors disappeared when they differentiated into LAK effectors, indicating that the activated LAK cells lacked AGM1. When examining the serologic phenotype of the LAK precursors in tumor-bearing hosts, we found that they lacked AGM1, which suggested that these LAK precursors were in an "activated" state. These cells were still Thy1-, and were thus different from fully activated LAK effectors which were Thy1+ cells, indicating that the full differentiation of LAK cells in vivo was arrested in the tumor-bearing hosts. We also found that the presence of small amounts of X-irradiated tumor cells prevented the generation of AK cells. These findings suggest that, in the tumor-bearing hosts, the presence of tumor cells triggers the activation of AK precursors; however, the same tumor cells may also be immunosuppressive, which prevents the full differentiation of AK precursors into AK effectors.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3100459     DOI: 10.1002/ijc.2910390218

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

1.  Augmented induction of antitumor cells in vivo by cyclophosphamide fails to benefit antitumor resistance of the host.

Authors:  K Ryoyama; C Ryoyama
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

2.  Inhibition of lymphokine-activated killer cell generation by cultured tumor cell lines in vitro.

Authors:  P J Guillou; P C Sedman; C W Ramsden
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

3.  AK cells were developed from NK cells during in vitro culture of allogeneic or F1 anti-parental stimulation: functional conversion in recognizing H-2 expression of target cells accompanied by phenotypical conversion.

Authors:  K Taniguchi; Y I Kawano; K Nomoto
Journal:  Immunology       Date:  1988-08       Impact factor: 7.397

4.  Immunosuppression in murine renal cell carcinoma. I. Characterization of extent, severity and sources.

Authors:  S K Gregorian; J R Battisto
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

5.  Surgical implications of tumour immunology.

Authors:  S S Somers
Journal:  Ann R Coll Surg Engl       Date:  1996-03       Impact factor: 1.891

6.  Immunosuppression in murine renal cell carcinoma. II. Identification of responsible lymphoid cell phenotypes and examination of elimination of suppression.

Authors:  S K Gregorian; J R Battisto
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

Review 7.  Intravenous ascorbic acid as an adjuvant to interleukin-2 immunotherapy.

Authors:  Samuel C Wagner; Boris Markosian; Naseem Ajili; Brandon R Dolan; Andy J Kim; Doru T Alexandrescu; Constantin A Dasanu; Boris Minev; James Koropatnick; Francesco M Marincola; Neil H Riordan
Journal:  J Transl Med       Date:  2014-05-13       Impact factor: 5.531

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.